Stockscreener 앱 받기
143.28
2.17%
3.1462
전일 마감가:
$140.13
열려 있는:
$139.68
하루 거래량:
1.34M
Relative Volume:
0.47
시가총액:
$30.89B
수익:
$606.42M
순이익/손실:
$-1.28B
주가수익비율:
-22.38
EPS:
-6.403
순현금흐름:
$-997.58M
1주 성능:
-2.16%
1개월 성능:
-4.26%
6개월 성능:
-2.74%
1년 성능:
+91.17%
1일 변동 폭
$138.82
$143.74
1주일 범위
$138.82
$150.27
52주 변동 폭
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
143.29 | 30.21B | 606.42M | -1.28B | -997.58M | -6.403 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.04 | 116.01B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.54 | 80.33B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
739.91 | 44.42B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.52 | 42.53B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
302.26 | 33.32B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-12-19 | 재개 | Truist | Buy |
| 2025-12-04 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-20 | 개시 | William Blair | Outperform |
| 2025-08-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Victory Capital Management Inc. Boosts Position in Insmed, Inc. $INSM - MarketBeat
Is Insmed Incorporated stock a safe investment in uncertain marketsInsider Selling & Free Technical Pattern Based Buy Signals - Naître et grandir
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA - Finviz
Institution Moves: What are the future prospects of Insmed IncorporatedBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed Breaks Below 200-Day Moving AverageNotable for INSM - Nasdaq
Insmed Grants Inducement Awards to 85 New Employees - Intellectia AI
GW&K Investment Management LLC Sells 672,513 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed hands 85 new employees stock units and long-term options - Stock Titan
Picton Mahoney Asset Management Sells 34,001 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmonary Arterial Hypertension Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therap - Barchart.com
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? - Yahoo Finance
Insmed, Inc. $INSM Shares Sold by Rafferty Asset Management LLC - MarketBeat
10 Stocks That Could Skyrocket in 2026 - Insider Monkey
Insmed’s BRINSUPRI Outperformance Puts Commercial Execution And Valuation In Focus - simplywall.st
Insmed Incorporated (INSM): Investor Outlook Reveals A Promising 42% Upside - DirectorsTalk Interviews
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations - Yahoo Finance
Insmed at TD Cowen Conference: Strategic Growth and Market Expansion - Investing.com South Africa
INSM: Strong Q4 launch, expanding access, and promising pipeline set stage for significant growth - TradingView
HC Wainwright Has Negative Outlook of Insmed FY2026 Earnings - MarketBeat
William Blair Investment Management LLC Has $223.94 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz
10 Unstoppable Stocks to Buy and Hold for the Next 3 Years - Insider Monkey
Insmed (INSM) director gifts shares and details family holdings - Stock Titan
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Artisan Partners Limited Partnership Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Why Insmed (INSM) Is Down 6.8% After Wider 2025 Losses But Rapid Brinsupri Launch Traction - simplywall.st
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
INSMED Chief Legal Officer Sells Shares Worth Over $3.8 Million - TradingView
Insmed (INSM) CLO exercises options and sells 24,774 shares - Stock Titan
Director David R. Brennan gifts 6,000 INSM (NASDAQ: INSM) shares in Form 4 - Stock Titan
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Brown Advisory Small-Cap Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
INSM (NASDAQ: INSM) reports Michael Smith sales and issuer plan issuances - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
H.C. Wainwright Remains a Buy on Insmed (INSM) - The Globe and Mail
INSM Stock Rating: Mizuho Lowers Price Target Amid Consistent Ou - GuruFocus
Mizuho Issues Pessimistic Forecast for Insmed (NASDAQ:INSM) Stock Price - MarketBeat
Insmed Incorporated (INSM) Gained from Its Lead Product ARIKAYCE - Yahoo Finance
HC Wainwright Comments on Insmed's Q1 Earnings (NASDAQ:INSM) - MarketBeat
Insmed chair and CEO Lewis sells $1.6m in stock By Investing.com - Investing.com Nigeria
Insmed chair and CEO Lewis sells $1.6m in stock - Investing.com
Insmed (INSM) Is Up 6.9% After BRINSUPRI Sales Beat Expectations And 2026 Target SetWhat's Changed - Yahoo Finance
H.C. Wainwright reiterates Buy on Insmed stock, $230 target By Investing.com - Investing.com UK
Insmed (INSM) CEO Lewis exercises options and sells 10,699 shares - Stock Titan
INSM: HC Wainwright & Co. Reiterates Buy Rating with $230 PT | I - GuruFocus
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
2.70%
자본화:
|
볼륨(24시간):